The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.

The total expression profiles of two medulloblastoma cell lines resistant to the preactivated form of cyclophosphamide (4-hydroperoxycyclophosphamide, 4-HC) were examined using the Affymetrix GeneChip U133A array. Our primary objective was to look for possible genes, other than the well-studied aldehyde dehydrogenases (ALDH) that may be involved in cyclophosphamide (CP) resistance in medulloblastomas. We present here the lists of the most highly upregulated [30 for D341 MED (4-HCR); 20 for D283 MED (4-HCR)] and downregulated [19 for D341 MED (4-HCR); 15 for D283 MED (4-HCR)] genes which may be involved in conferring CP-resistance to the two medullobalstoma cell lines. The lists of genes from the two sublines almost had no overlap, suggesting different mechanisms of CP-resistance. One of the most noteworthy upregulated gene is TAP1 [90-fold increase in D341 MED (4-HCR) relative to D341 MED]. TAP1, a protein belonging to the ABC transporter family is normally involved in major histocompatibility class I (MHC I) antigen processing. This suggests the possible role of multidrug resistance (MDR), albeit atypical (which means it does not involve the usual MDR1 and MRP glycoproteins), in medulloblastoma's CP-resistance. Apart from TAP1, a number of other genes involved in MHC1 processing were upregulated in D341 MED (4HCR). D341 MED (4-HCR) also had a 20-fold increase in the expression of the aldo-keto reductase gene, AKR1B10, which may deactivate the reactive cyclophosphamide metabolite, aldophosphamide. For D283 MED (4-HCR), the most notable increase in expression is that of ALDH1B1, a member of the aldehyde dehydrogenase (ALDH) family of proteins.

[1]  F. Kokocinski,et al.  Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. , 2004, Cancer research.

[2]  H. K. Kim,et al.  Gene expression signatures associated with the resistance to imatinib , 2006, Leukemia.

[3]  Robert Tampé,et al.  The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. , 2004, Physiology.

[4]  Z. Duan,et al.  Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  C. Fenselau,et al.  A biologically active metabolite of cyclophosphamide. , 1973, Cancer research.

[6]  M. P. Gamcsik,et al.  Mechanisms of resistance against cyclophosphamide and ifosfamide: can they be overcome without sacrificing selectivity? , 2002, Cancer treatment and research.

[7]  Guoyao Wu,et al.  Glutathione metabolism and its implications for health. , 2004, The Journal of nutrition.

[8]  D. Bigner,et al.  Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and-resistant medulloblastoma cell lines , 1995, Cancer Chemotherapy and Pharmacology.

[9]  N. Sládek Metabolism of oxazaphosphorines. , 1988, Pharmacology & therapeutics.

[10]  D. Owen,et al.  Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. , 2005, The Journal of clinical investigation.

[11]  Lakshmaiah Sreerama,et al.  Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study , 2002, Cancer Chemotherapy and Pharmacology.

[12]  Yao-Tseng Chen,et al.  CT10: A new cancer‐testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational‐difference analysis , 2000, International journal of cancer.

[13]  O. M. Friedman,et al.  Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. , 1977, Cancer research.

[14]  Je-Jung Lee,et al.  Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation , 2007, American journal of hematology.

[15]  M. Volm,et al.  O6‐methylguanine‐DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts , 1998, International journal of cancer.

[16]  J. Trojanowski,et al.  Establishment and Characterization of the Human Medulloblastoma Cell Line and Transplantable Xenograft D283 Med , 1985, Journal of neuropathology and experimental neurology.

[17]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[18]  Jeffrey C. Allen,et al.  Preradiation chemotherapy for newly diagnosed childhood brain tumors. A modified phase II trial , 1983, Cancer.

[19]  M. Makuuchi,et al.  Expression of the MAGE gene family in human hepatocellular carcinoma , 1999, Cancer.

[20]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[21]  V. Speirs,et al.  Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro. , 2007, International journal of oncology.

[22]  D. Bigner,et al.  Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma. , 2002, Molecular cancer therapeutics.

[23]  M. Dolan,et al.  Modulation of cyclophosphamide activity by O 6-alkylguanine-DNA alkyltransferase , 1999, Cancer Chemotherapy and Pharmacology.

[24]  K. Uzawa,et al.  Establishment and characterization of a cisplatin-resistant cell line, KB-R, derived from oral carcinoma cell line, KB. , 2007, International journal of oncology.

[25]  A. Pegg,et al.  The role of human O(6)-alkylguanine-DNA alkyltransferase in promoting 1,2-dibromoethane-induced genotoxicity in Escherichia coli. , 2000, Mutation research.

[26]  J. Hilton,et al.  Pharmacology of cyclophosphamide and metabolites. , 1981, Cancer treatment reports.

[27]  B. Têtu,et al.  Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. , 2006, International journal of oncology.

[28]  A. Pegg Properties of mammalian O6-alkylguanine-DNA transferases. , 1990, Mutation research.

[29]  X. Wu,et al.  Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Robert Wechsler-Reya,et al.  BIN1 is a novel MYC–interacting protein with features of a tumour suppressor , 1996, Nature Genetics.

[31]  T. Flynn,et al.  Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. , 2003, The Biochemical journal.

[32]  R. Tampé,et al.  Function of the transport complex TAP in cellular immune recognition. , 1999, Biochimica et biophysica acta.

[33]  A. Monks,et al.  Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells , 2002, British Journal of Cancer.

[34]  L. Helson,et al.  High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. , 1981, Journal of neurosurgery.

[35]  H. Friedman,et al.  Cyclophosphamide resistance in medulloblastoma. , 1992, Cancer research.

[36]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[37]  Yana Zhang,et al.  Cancer‐testis antigens in haematological malignancies , 2007, British journal of haematology.

[38]  Stephen B. Howell,et al.  Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells , 2006, Cancer Chemotherapy and Pharmacology.

[39]  K. Früh,et al.  Antigen presentation by MHC class I and its regulation by interferon gamma. , 1999, Current opinion in immunology.

[40]  E. D. de Vries,et al.  Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation , 2004, British Journal of Cancer.

[41]  H. Friedman,et al.  Cellular mechanisms of cyclophosphamide resistance: model studies in human medulloblastoma cell lines. , 2002, Cancer treatment and research.

[42]  C. Fenselau,et al.  Alkylating properties of phosphoramide mustard. , 1976, Cancer research.

[43]  U. Boehm,et al.  Cellular responses to interferon-gamma. , 1997, Annual review of immunology.

[44]  N. Sládek Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. , 1999, Current pharmaceutical design.

[45]  Ingrid Lönnstedt Replicated microarray data , 2001 .

[46]  J. Trojanowski,et al.  Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc. , 1988, The American journal of pathology.

[47]  P. McHugh,et al.  Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. , 2001, The Lancet. Oncology.

[48]  M. Dolan,et al.  Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. , 2004, Molecular cancer therapeutics.

[49]  Yusuke Nakamura,et al.  Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. , 2003, Cancer research.

[50]  T. Poggio,et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.

[51]  P. Cresswell,et al.  Mechanisms of MHC class I--restricted antigen processing. , 1998, Annual review of immunology.

[52]  J. Bakke,et al.  Metabolism of cyclophosphamide by sheep. , 1972, Journal of agricultural and food chemistry.

[53]  N. Sládek,et al.  NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide. , 1993, Biochemical pharmacology.

[54]  Laura Smith,et al.  Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model , 2007, Acta oncologica.

[55]  S. Shammah,et al.  Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. , 1996, Blood.

[56]  D. Schadendorf,et al.  Enhanced expression of human ABC‐transporter tap is associated with cellular resistance to mitoxantrone , 2001, FEBS letters.

[57]  Miki Ohira,et al.  LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma. , 2005, Cancer research.

[58]  A. Pifferi,et al.  The antitumour activity of alkylating agents is not correlated with the levels of glutathione, glutathione transferase and O6-alkylguanine-DNA-alkyltransferase of human tumour xenografts. EORTC SPG and PAMM Groups. , 1998, European journal of cancer.

[59]  Shufeng Zhou,et al.  Metabolism and Transport of Oxazaphosphorines and the Clinical Implications , 2005, Drug metabolism reviews.

[60]  T. A. Connors,et al.  Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. , 1974, Biochemical pharmacology.

[61]  T. Witham,et al.  l-Buthionine Sulfoximine Potentiates the Antitumor Effect of 4-Hydroperoxycyclophosphamide When Administered Locally in a Rat Glioma Model , 2001, Neurosurgery.

[62]  C. Shimizu,et al.  Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients , 2006, Breast Cancer Research and Treatment.